Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Fiona Simpkins, M.D.

Fiona Simpkins, M.D.

faculty photo
Assistant Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania
Department: Obstetrics and Gynecology

Contact information
Jordan Center for Gynecologic Oncology at Penn Perelman Center for Advanced Medicine
3400 Civic Center Blvd., 3rd Floor West
Philadelphia, PA 19104
Office: 215-662-3318
Fax: 215-349-5849
Education:
B.S (Biology)
University of California, Los Angeles, CA, 1993.
(Clinical Research Training Award)
University of California, Los Angeles, CA, 1995.
M.D.
Temple University School of Medicine, Philadelphia, PA, 1999.
(Molecular Signaling Section, Cancer Research Training Fellowship)
NIH, NCI, 2005.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Selected Publications

Erin George, Hyoung Kim, Clemens Krepler, Brandon Wenz, Mehran Makvandi, Janos L. Tanyi, Eric Brown, Rugang Zhang, Patricia Brafford, Stephanie Jean, Robert H. Mach, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Mark Morgan, Xiaochen Zhang, Robert Soslow, Ronny Drapkin, Neil Johnson, Ying Zheng, George Cotsarelis, Katherine L. Nathanson, and Fiona Simpkins : A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight January 2017.

Kim H, George E, Ragland RL, Rafail S, Zhang R, Krepler C, Morgan M, Herlyn M, Brown EJ, Simpkins F.: Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models. Clin. Cancer Res. Page: pii: clincanres.2273.2016, Dec 2016.

Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.: Ring domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clinical Investigation 126(8):: 3145-57, Aug. 2016.

Dean LT, Zhang X, Latif N, Giuntoli R, Lin L, Haggerty A, Kim S, Shalowitz D, Stashwick C, Simpkins F, Burger R, Morgan M, Ko E, Schmitz K.: Race-based disparities in loss of functional independence after hysterectomy for uterine cancer. Support Care Cancer 24(8):: 3573-80, August 2016.

Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.: RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest. Page: 1;126(8):3145-57, Aug 2016.

George E, Kim H, Ragland R, Brown E, Butler L, Gilad O, Tanyi J, Zhang R, Krepler C, Lee R, Morgan M, Burger R, Ko E, Kim S, Herlyn M, Simpkins F: : Capitalizing on synthetic lethality in homologous recombination deficient high grade serous ovarian cancers with a novel ATR inhibitor. Poster and published as abstract for the SGO meeting. San Diego, CA, April 2016.

Simpkins F, Drake R, Michener C, Rose, P.: Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma, Journal of Gynecologic Cancer April 2016.

Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford P, Gao W, Lu Y, Mills GB, Slingerland JM, Simpkins F: MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res 22(4):935-47, Feb 2016.

George E, Kim H, Tanyi J, Ragland R, Brown E, Zhang R, Brafford P, Sproesser K, Beqiri M, Vultur A, Krepler C, Lee R, Weis B, Nathanson K, Lu Y, Mills G, Makvandi M, Mach R, Morgan M, Herlyn M, Simpkins F: A novel orthotopic ovarian patient derived xenograft model platform to investigate novel therapies for BRCA deficient ovarian cancers. Poster, AACR, New Orleans, LA, Feb 2016.

Zhang X, Haggerty AF, Brown JC, Giuntoli R 2nd, Lin L, Simpkins F, Dean LT, Ko E, Morgan MA, Schmitz KH: The prescription or proscription of exercise in endometrial cancer care. Gynecol Oncol 139(1):155-9, Oct 2015.

back to top
Last updated: 01/13/2017
The Trustees of the University of Pennsylvania